Last updated: 2026-09-06 15:13:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PharmaCyte Biotech, Inc. (PMCB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.49, with a market capitalization of $5.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.47 to $1.51. This page covers its latest market performance, valuation, price trends and company information.
$5.16M | |
$0.49 | |
$9.98 | |
$0.47 | |
$0.49 | |
44.17K | |
-- | |
-- | |
$1.51 | |
$0.47 | |
4.68% | |
-- |
PharmaCyte Biotech, Inc. (PMCB) last closed at $0.49 as of 2026-09-04 21:11:00, unchanged from the previous close of $0.49.
During the latest regular trading session, PMCB traded between $0.47 and $9.98, with a volume of 44.17K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, PharmaCyte Biotech, Inc. (PMCB) moved from $0.52 to $0.49, representing a decline of 6.54% ($0.03).
The stock traded between $0.49 and $0.52 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 75.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.5%
PMCB is currently trading at $0.49, placing it 1.5% of the way from its 52-week low of $0.47 to its 52-week high of $1.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PharmaCyte Biotech, Inc. (PMCB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.